BENITIONSClinical Trial Intelligence

Sphenopalatine Ganglion Nerve Block vs. Elavil for Treatment of Transformed Migraines

4期 提前终止 NCT02090998

适应症Transformed Migraine, Chronic Daily Headache
分期4期
申办方Rutgers, The State University of New Jersey
状态提前终止
受试者人数10 人
干预(药物)SPG Block with 5% Lidocaine gel, Amitriptyline
开始日期2014年5月
完成日期2020年3月16日
结果公布日2021年12月29日

摘要

This study will compare a local anesthetic technique that has been used to treat subjects suffering from transformed migraines (chronic migraines) versus medical management with traditional antidepressant Amitriptyline / Elavil. Subjects will be randomized into one of two treatment groups to compare the safety and efficacy of the therapies. Subjects will recieve either sphenopalatine ganglion nerve block with 5% lidocaine gel into the nasopharynx or medical management with traditional antidepressants, Elavil, to produce a reduction in the frequency and severity of the headache. We propose that there will be a difference in the outcomes when comparing the two methods of treating transformed migraines and that one research arm will result in more patient satisfaction and greater efficacy in the treatment of subjects

Number of Daily Headaches

Study Day 1 through Study Day 30 · Number of Daily Headaches

Amitriptyline / Elavil20.5 ± 0.5 Number of Daily Headaches
SPG Nerve Block With Lidocaine 5% Gel13.4 ± 10.4 Number of Daily Headaches

在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文

同一适应症的其他试验

全部试验

本页整理自 ClinicalTrials.gov 的公开数据,不构成医疗建议,也不构成投资建议。请务必咨询专业医师。